Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Deffered Revenue: 2013-2017

Historic Non-Current Deffered Revenue for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Sep 2017 value amounting to $1.2 million.

  • Amphastar Pharmaceuticals' Non-Current Deffered Revenue rose 623.21% to $1.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $1.2 million, marking a year-over-year increase of 623.21%. This contributed to the annual value of $97,000 for FY2016, which is 92.76% down from last year.
  • As of Q3 2017, Amphastar Pharmaceuticals' Non-Current Deffered Revenue stood at $1.2 million, which was up 187.23% from $423,000 recorded in Q2 2017.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-Current Deffered Revenue registered a high of $2.6 million during Q4 2013, and its lowest value of $97,000 during Q4 2016.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Non-Current Deffered Revenue value was $1.2 million (recorded in 2016), while the average stood at $895,364.
  • In the last 5 years, Amphastar Pharmaceuticals' Non-Current Deffered Revenue slumped by 92.76% in 2016 and then spiked by 623.21% in 2017.
  • Amphastar Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $2.6 million in 2013, then decreased by 24.50% to $2.0 million in 2014, then crashed by 32.44% to $1.3 million in 2015, then crashed by 92.76% to $97,000 in 2016, then surged by 623.21% to $1.2 million in 2017.
  • Its last three reported values are $1.2 million in Q3 2017, $423,000 for Q2 2017, and $280,000 during Q1 2017.